Executive Wealth Management LLC lessened its position in PRA Health Sciences Inc (NASDAQ:PRAH) by 2.5% in the 1st quarter, HoldingsChannel reports. The firm owned 9,520 shares of the medical research company’s stock after selling 249 shares during the period. Executive Wealth Management LLC’s holdings in PRA Health Sciences were worth $1,050,000 at the end of the most recent quarter.
A number of other large investors have also recently modified their holdings of PRAH. Financial Gravity Wealth Inc. bought a new stake in PRA Health Sciences in the first quarter valued at approximately $53,000. CENTRAL TRUST Co increased its stake in PRA Health Sciences by 28.2% in the first quarter. CENTRAL TRUST Co now owns 842 shares of the medical research company’s stock valued at $93,000 after purchasing an additional 185 shares in the last quarter. Enlightenment Research LLC bought a new stake in PRA Health Sciences in the fourth quarter valued at approximately $101,000. Carroll Financial Associates Inc. increased its stake in PRA Health Sciences by 7.6% in the first quarter. Carroll Financial Associates Inc. now owns 1,517 shares of the medical research company’s stock valued at $167,000 after purchasing an additional 107 shares in the last quarter. Finally, Quantamental Technologies LLC bought a new stake in PRA Health Sciences in the fourth quarter valued at approximately $221,000. 98.14% of the stock is owned by hedge funds and other institutional investors.
PRAH has been the subject of several research reports. Robert W. Baird increased their price objective on shares of PRA Health Sciences from $119.00 to $122.00 and gave the stock an “outperform” rating in a research report on Thursday, February 28th. BidaskClub downgraded shares of PRA Health Sciences from a “hold” rating to a “sell” rating in a research report on Friday, April 19th. Wolfe Research initiated coverage on shares of PRA Health Sciences in a research report on Tuesday, April 2nd. They set a “market perform” rating for the company. ValuEngine downgraded shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, April 13th. Finally, SunTrust Banks increased their price objective on shares of PRA Health Sciences to $120.00 and gave the stock an “average” rating in a research report on Monday, March 4th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the company’s stock. PRA Health Sciences currently has an average rating of “Hold” and a consensus target price of $113.22.
PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings data on Wednesday, February 27th. The medical research company reported $1.21 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.18 by $0.03. The company had revenue of $729.65 million during the quarter, compared to the consensus estimate of $750.67 million. PRA Health Sciences had a net margin of 5.50% and a return on equity of 26.87%. On average, research analysts anticipate that PRA Health Sciences Inc will post 4.62 EPS for the current fiscal year.
About PRA Health Sciences
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Recommended Story: Bond
Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.